Lupus erythematosus
☆ Katika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa.
Inaonekana kama erithema ya purplish kidogo.
Upele wa kipepeo ambao kwa kawaida huonekana usoni.
References
Kutambua na kuainisha cutaneous lupus erythematosus (CLE) huleta changamoto za uchunguzi, kuitofautisha na systemic lupus erythematosus na uhusika wa ngozi. Tafiti za hivi majuzi zimeangazia vipengele vya kijeni, kimazingira, na vya kinga vinavyotokana na CLE. Uingizaji wa madawa ya kulevya umeibuka kama mojawapo ya vichochezi muhimu zaidi vya CLE. Matibabu huhusisha matibabu ya kimaadili na ya kimfumo, ikiwa ni pamoja na baiolojia ya kuahidi (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , yenye ufanisi ulioonyeshwa katika majaribio ya kimatibabu.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) inashughulikia maswala mbalimbali ya ngozi, ambayo baadhi yanaweza kuhusisha matatizo mapana ya kiafya. Imeainishwa katika aina tofauti, kama vile acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE inajumuisha discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus ni kundi la magonjwa ya autoimmune ambayo yanaweza kuathiri sehemu mbalimbali za mwili. Baadhi ya aina, kama vile systemic lupus erythematosus (SLE) , huathiri viungo vingi, huku nyingine, kama cutaneous lupus erythematosus (CLE) , huathiri sana ngozi. Tunapanga aina tofauti za CLE kulingana na mchanganyiko wa ishara za kliniki, uchunguzi wa tishu na vipimo vya damu, lakini kuna tofauti nyingi kati ya watu binafsi. Matatizo ya ngozi mara nyingi hujitokeza kutokana na sababu kama vile mwanga wa jua, uvutaji sigara au dawa fulani.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Sababu ya lupus erythematosus haijulikani wazi. Miongoni mwa mapacha wanaofanana, ikiwa mmoja ameathiriwa kuna uwezekano wa 24% na mwingine pia. Homoni za ngono za kike, mwanga wa jua, uvutaji sigara, upungufu wa vitamini D, na maambukizo fulani pia yanaaminika kuongeza hatari.
Matibabu yanaweza kujumuisha NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, na methotrexate. Ingawa corticosteroids ni nzuri, matumizi ya muda mrefu husababisha madhara.